What's breaking now, across thousands of outlets.
Gilead Sciences is to start late-stage trials of its oral α4β7 inhibitor in ulcerative colitis next year, after data from a Phase 2 dose-finding trial suggested that the drug looked better than rival products. After ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
A public information stand, the reading of a manifesto and a pink balloon release were held in Plaza de la Constitución on 19 October.
Plus news about Longwood's next fund and Ryzumvi's label expansion. EyePoint drug fails, biotech halves staff: The Watertown, MA-based biotech is letting go of 53% of its positions after its…
A joint research group led by Ryo Tanifuji and Hiroki Oguri from the University of Tokyo and Yoshikazu Tanaka from Tohoku University has visualized SacC, an enzyme that plays a key role in building…
(MedPage Today) -- Halley Froehlich, PhD, was sure she'd spend her scientific career in the U.S. Her family has been in America since the 1700s.
Medication recalls and expirations are a routine part of pharmacy operations, but managing them often requires significant time, coordination and attention to detail.
The goals of the new bodies are to address women’s health research gaps to improve health outcomes across the lifespan.
